Nilufer — Neuroaffective medicines

NILU-001

Social Anxiety

V1bR Antagonist

Discovery

Pre-Clinical

Phase I-II

Phase III

Limerence

V1aR Antagonist

Discovery

Pre-Clinical

Phase I-II

Phase III

Peri-Op Cognitive Disorder

PDE4/PDE10 Inhibitor, MIF Antagonist

Discovery

Pre-Clinical

Phase I-II

Phase III

Mechanism: Open chest surgeries can trigger neuroinflammation, microglial activation, and microvascular injury; our drug is proven to lower proinflammatory cytokines, suppresses microglia, and supports neurotrophic pathways.
Severity: Memory and attention problems, slower processing, mood changes, loss of independence, reduced employability, increased hospitalization cost, caregiver burden.
US Demographics: About 150-200k CABG procedures each year; persistent impairment in 10-20 percent, or about 15-40k new patients annually.

Visual Snow Subtype

ASIC1a Antagonist

Discovery

Pre-Clinical

Phase I-II

Phase III

DNA-Protectant

Polyamine Analog

Discovery

Pre-Clinical

Phase I-II

Phase III

Mechanism: Tautomeric proton shifts cause base mispairing and raise DNA mutation rate; this analog aims to stabilize base pairing and reduce replication errors.
Severity: Genomic instability drives cancer, neurodegeneration, and faster biological aging, reducing independence and mental well being.
US Demographics: Universal in principle; every person accrues mutations. Older adults 65 plus, about 62 million, face the highest annual burden.